Organic solvents — most commonly ethanol — are indispensable facilitators of lipid dissolution and molecular mixing during LNP self-assembly. Yet the moment nanoparticles take shape, these same solvents become liabilities. Residual solvents compromise colloidal stability by plasticizing lipid membranes, accelerate hydrolytic degradation of nucleic acid payloads, interfere with electrostatic ionizable lipid-payload complexation, and at sufficient concentrations present cytotoxicity concerns that preclude direct biological use.
Solvent removal therefore occupies a unique position in the LNP manufacturing workflow: it is simultaneously a purification operation, a formulation-defining process, and a critical quality attribute (CQA) control point. The method chosen determines not only residual solvent levels but also particle size distribution, encapsulation efficiency, zeta potential, and batch-to-batch consistency. This resource examines the full spectrum of solvent removal strategies — organized by method type, production scale, payload sensitivity, and solvent chemistry — to provide a decision-oriented framework for process design.
At the laboratory scale, solvent removal strategies prioritize simplicity, accessibility, and compatibility with small batch volumes typical of early formulation screening. While each method has throughput limitations that preclude direct translation to commercial manufacturing, the process understanding developed at this scale informs the selection and parameterization of scalable technologies later in development.
Principle: Lipids are dissolved in volatile organic solvents (typically chloroform, methanol, or chloroform-methanol mixtures) in a round-bottom flask. Controlled rotation under reduced pressure and mild heating (318-333 K) drives solvent evaporation, leaving a homogeneous lipid film. Subsequent hydration with aqueous buffer — optionally containing the payload — produces a crude LNP dispersion.
Advantages: Organic solvents are removed entirely before payload introduction, making this the gentlest option for solvent-sensitive cargos such as proteins and peptides. Equipment is simple and universally available.
Limitations: Produces inherently broad particle size distributions (PDI often >0.3), requiring downstream sonication or extrusion. Batch-to-batch reproducibility depends on operator technique. High-boiling-point solvents and azeotropic mixtures can leave trace residues.
Principle: A lipid-ethanol solution is rapidly injected into excess aqueous buffer. The sudden reduction in solvent power triggers spontaneous lipid precipitation into nanoparticles. Ethanol is subsequently removed by passive diffusion, gentle evaporation, or downstream purification.
Advantages: Fast — a batch can be prepared in minutes. Minimal equipment required. Conceptual precursor to modern microfluidic LNP production.
Limitations: High initial ethanol concentration (10-30% v/v) can destabilize nucleic acid payloads and promote particle fusion. Must be paired with dialysis, TFF, or centrifugal ultrafiltration for adequate ethanol removal. Uncontrolled mixing produces larger particles (80-200 nm) with higher PDI than microfluidic approaches.
Principle: LNP suspension is placed inside a dialysis cassette or tubing (MWCO 10-100 kDa) and immersed in a large volume of solvent-free buffer. Solvent molecules diffuse passively across the membrane while LNPs are retained. Periodic buffer replacement maintains the concentration gradient.
Advantages: Exceptionally gentle — no applied pressure or shear forces. Low equipment cost. Preferred for early-stage development of shear-sensitive formulations, including protein encapsulation in LNPs.
Limitations: Processing times of 12-24 hours expose payloads to extended solvent contact. Inherently batch-size dependent. Cannot concentrate the sample. Limited real-time monitoring capability. Unsuitable beyond a few hundred milliliters.
Table 1. Key Parameters for Dialysis-Based LNP Solvent Removal.
| Parameter | Recommended Range | Impact |
| Membrane MWCO | 10-100 kDa | Lower MWCO retains smaller payloads but slows solvent diffusion |
| Dialysate-to-Sample Ratio | 100:1 to 500:1 | Larger ratios sustain stronger diffusion gradients |
| Buffer Exchange Frequency | Every 4-8 hours | Frequent exchanges prevent gradient collapse |
| Temperature | 4-25 °C (payload-dependent) | Higher temperature accelerates diffusion but may destabilize cargo |
Principle: Centrifugal force drives solvent and small solutes through a membrane filter (MWCO 10-100 kDa) while retaining LNPs. Simultaneously achieves solvent removal, buffer exchange, and sample concentration in 30-60 minutes.
Advantages: Dramatically faster than dialysis. Concentrates sample as it purifies. Ideal for parallel processing of multiple formulation variants during screening.
Limitations: Centrifugal force creates a concentrated polarization layer at the membrane surface, promoting aggregation. Shear forces can damage large mRNA constructs. Throughput limited to ~50 mL by rotor capacity and filter unit size.
As LNP programs advance toward manufacturing, solvent removal must satisfy more demanding requirements: reproducible performance across batch sizes from milliliters to thousands of liters, closed-system compatibility, PAT integration, and documented CPP-CQA relationships.
Principle: LNP suspension flows tangentially across a semipermeable membrane. The crossflow geometry continuously sweeps retained particles away from the surface, preventing cake-layer formation. Solvent and small solutes pass into the permeate; LNPs are retained and recirculated. TFF simultaneously achieves solvent removal, buffer exchange (diafiltration), and product concentration.
Membrane Selection: Hollow fiber modules are preferred for LNPs — their laminar flow generates lower shear than flat-sheet cassettes. Modified polyethersulfone (mPES) is widely used for its hydrophilicity and low protein binding. MWCO of 100 kDa efficiently passes ethanol (46 Da) while retaining 40-120 nm LNPs.
Critical Salt Introduction Protocol: During initial solvent removal, diafiltration buffer must be low-ionic-strength (citrate buffer pH 4 or ultrapure water). High salt during this phase screens electrostatic ionizable lipid-RNA interactions, causing payload leakage. Only after ethanol drops below ~1% should buffer be gradually transitioned to physiological formulation buffer (e.g., PBS). This stepwise approach prevents osmotic shock and ionic screening.
For teams transitioning toward scalable manufacturing, LNP process optimization services systematically map the TFF operating space to maximize solvent clearance while preserving CQAs. Comprehensive lipid nanoparticle manufacturing support integrates solvent removal with upstream formulation and downstream fill-finish.
Table 2. Critical TFF Parameters for LNP Solvent Removal.
| Parameter | Recommended Range | Rationale | Failure Mode If Exceeded |
| Membrane MWCO | 100-300 kDa | Retains LNPs; allows ethanol and salts to pass | Below 100 kDa: restricted flux; above 300 kDa: potential LNP loss |
| TMP | < 2.5 psi | Minimizes shear-induced stress on LNP structure | mRNA leakage, lipid bilayer disruption, particle deformation |
| Permeate Flux | 10-30 LMH | Balances speed with fouling and polarization control | >30 LMH: rapid fouling, aggregation;<10 LMH: excessive processing time |
| Initial Diafiltration Buffer | Low ionic strength (citrate pH 4, or water) | Preserves electrostatic lipid-RNA binding during ethanol removal | High salt: disrupted complexation, RNA leakage, EE% loss |
| Salt Introduction Threshold | Ethanol < 1% | Ensures LNP stability before osmotic and ionic challenge | Premature salt: osmotic shock, aggregation, payload release |
| Diafiltration Volumes | 5-10 diavolumes | Achieves >95% ethanol removal | Insufficient volumes: residual ethanol above target |
Principle: Uses the same tangential flow principle as TFF but with modules containing hundreds to thousands of narrow-diameter hollow fibers (0.5-1.0 mm ID). LNP suspension flows through fiber lumens; permeate passes radially outward through porous walls.
Key Advantage: High membrane surface area per unit volume combined with laminar flow minimizes shear stress — ideal for shear-sensitive LNPs at intermediate and large scales.
Continuous Manufacturing Integration: Hollow fiber modules can directly couple to microfluidic LNP formation, eliminating hold time between particle formation and purification. The primary challenge is maintaining uniform TMP and flux distribution across all fibers — variations create zones of elevated shear or stagnant flow.
BOC Sciences develops solvent removal workflows around your formulation, payload, solvent system, and process requirements, supporting method development and scale-up from laboratory studies to industrial production.
Principle: The LNP stream exiting a microfluidic mixer is immediately contacted with a controlled flow of dilution buffer, reducing ethanol concentration in a stepwise or gradient fashion — integrating solvent management directly into particle formation.
Advantages:
For teams interested in continuous production, microfluidic LNP production services at BOC Sciences provide access to continuous processing platforms with integrated solvent management.
Principle: These are finishing technologies — not alternatives to TFF or dialysis for primary ethanol removal — that remove water and residual volatiles from LNP suspensions to produce stable solid dosage forms. Spray drying atomizes the suspension into heated gas; lyophilization freezes the suspension and sublimes ice under vacuum.
Purpose: Extend shelf life from weeks/months (liquid) to years (solid); enable ambient or refrigerated storage instead of -70 °C to -20 °C.
Critical Requirement: Cryoprotectants (trehalose, sucrose at 5-10% w/v) must be added before drying to form a protective glassy matrix. Post-reconstitution lipid nanoparticle characterization — particle size, PDI, zeta potential, encapsulation efficiency — must verify that drying has not compromised quality.
Principle: Eliminates organic solvents from manufacturing entirely. Supercritical CO2 (scCO2: >304 K, >73.8 bar) dissolves lipids and facilitates particle formation without ethanol or chloroform. LNP formation occurs by expanding scCO2-lipid solution into aqueous phase, or using scCO2 as an antisolvent.
Advantages: CO2 is non-toxic, non-flammable, inexpensive, and leaves zero residue. Uniquely gentle for protein/peptide cargos intolerant of ethanol exposure.
Barriers to Adoption: High capital cost of high-pressure equipment. Complex process development requiring supercritical fluid expertise. Particle size control does not yet match microfluidic precision. Currently research-stage, though long-term potential for solvent-sensitive biologics remains compelling.
No single solvent removal strategy is optimal for all LNP formulations. The payload — its molecular weight, charge density, shear sensitivity, temperature tolerance, and solvent vulnerability — dictates the acceptable operating window. The table below summarizes the strategy for each major cargo class.
Challenge: mRNA (600-1,500 kDa) is sensitive to shear, temperature, pH, and RNase. Ethanol at 30-40% v/v during microfluidic mixing must be reduced to trace levels within hours.
Method: TFF is the only commercially viable approach. Key parameters: TMP<2.5 psi, low-salt citrate buffer (pH 4) for initial diafiltration, ethanol <1% before PBS introduction, cryoprotectant (sucrose/trehalose 5-10% w/v) for lyophilization or frozen storage. Processing completed within 4-8 hours.
For mRNA-based programs, lipid nanoparticles for mRNA delivery services encompass formulation, process development, and analytical characterization.
Challenge: siRNA (~13 kDa) is 50-100× smaller than mRNA, making it more prone to diffusion-driven leakage during solvent exchange. Ionizable lipids (e.g., DLin-MC3-DMA) require pH ~4 throughout removal to maintain electrostatic binding.
Method: TFF with lower-MWCO membranes (30-50 kDa), slower flux (10-15 LMH), and more diafiltration volumes (8-12). Dialysis remains viable for early-stage development. For specialized siRNA-LNP development, lipid nanoparticles for siRNA delivery expertise addresses these formulation-specific considerations.
Challenge: Drug partitioning between lipid core, aqueous phase, and organic solvent during removal depends on logP. Hydrophilic drugs (logP<3) can redistribute into permeate during TFF, progressively reducing drug loading.
Method: Rotary evaporation (thin-film hydration) for highly lipophilic drugs (logP >4). TFF with high flux and minimal diafiltration volumes for hydrophilic drugs. Remote loading — active drug loading into pre-formed, solvent-free LNPs via pH/ion gradients — can decouple drug encapsulation from solvent removal entirely.
Challenge: Proteins and peptides are the most solvent-sensitive payload class. Ethanol exposure causes irreversible unfolding, aggregation, and loss of activity.
Method: Thin-film hydration with solvent removed before cargo introduction is the preferred approach. When post-formation removal is unavoidable, dialysis is gentlest. If TFF is required: 4 °C operation, TMP<1.5 psi, flux <10 LMH. Supercritical CO2 offers a solvent-free alternative. LNP-based peptide delivery and lipid nanoparticles for antigen delivery at BOC Sciences include solvent removal method selection as a core development component.
Challenge: Cas9 RNP (~190 kDa) has a complex surface charge distribution. Both protein and RNA components are susceptible to solvent- and shear-induced damage; the RNP complex can dissociate under unfavorable conditions.
Method: The preferred strategy decouples solvent removal from cargo loading: pre-formed empty LNPs undergo TFF under conditions optimized for lipids alone, then Cas9 RNP is actively loaded via pH gradient. When co-formulation is required: TFF at<10 °C, TMP <1.5 psi, very gradual solvent removal. Lipid nanoparticles for CRISPR RNP delivery services provide tailored process development for this demanding application.
Challenge: Two-stage removal: organic solvent (ethanol) removed first, then water removed by lyophilization or spray drying. Cryoprotectants must be present during water removal to prevent LNP fusion.
Method: TFF for ethanol removal → cryoprotectant addition (trehalose/sucrose 5-10% w/v) → lyophilization or spray drying. Critical quality check: after reconstitution, particle size, PDI, zeta potential, and encapsulation efficiency must match pre-dried specifications.
Table 3. Solvent Removal Strategy by LNP Payload Type — Comparative Summary.
| Payload | Core Challenge | Preferred Method | Critical Control Parameter | Typical Scale |
| mRNA | Shear sensitivity; pH-dependent lipid-mRNA binding | TFF | TMP<2.5 psi; low-salt initial buffer; ethanol <1% before PBS | Commercial (thousands of liters) |
| siRNA | Small size (~13 kDa); diffusion-driven leakage | TFF (low MWCO) or dialysis | MWCO 30-50 kDa; flux 10-15 LMH; pH 4 maintained | Pilot to commercial |
| Small-Molecule Drug | LogP-dependent partitioning during removal | Rotary evaporation (logP >4) or TFF (logP<3) | Minimal diafiltration for hydrophilic drugs; remote loading option | Laboratory to pilot |
| Protein / Peptide | Solvent-induced denaturation; shear aggregation | Dialysis or thin-film hydration | 4 °C; TMP<1.5 psi if TFF; supercritical CO2 alternative | Laboratory to pilot |
| CRISPR-Cas9 RNP | Dual protein-RNA sensitivity; complex dissociation | Pre-formed LNP loading or low-T TFF | <10 °C; TMP <1.5 psi; active loading preferred | Preclinical to process development |
| Solid-State LNP | Two-stage removal; cryoprotectant integration | TFF → Cryoprotectant → Lyophilization | Cryoprotectant 5-10% w/v; reconstitution QC | Laboratory to commercial |
Submit your LNP solvent system, payload, and current process conditions. BOC Sciences will develop a tailored solvent removal strategy that supports efficient clearance while preserving particle quality and payload integrity.
The choice of organic solvent is driven by lipid solubility requirements, the LNP formation method, and the downstream removal strategy. Different solvents present fundamentally different removal challenges based on boiling point, vapor pressure, water miscibility, density, and toxicity profile. The table below provides a systematic overview.
Table 4. Organic Solvents in LNP Manufacturing — Properties, Applications, and Removal Strategies.
| Solvent | Application in LNP Manufacturing | Key Properties for Removal | Recommended Removal Method |
| Ethanol | Primary solvent for microfluidic mixing and solvent injection; dissolves ionizable lipids, helper lipids, cholesterol, PEG-lipids; used at 25-40% v/v; dominant in mRNA/siRNA-LNP manufacturing | BP 78 °C; fully water-miscible; Class 3 solvent; small molecule (46 Da) easily passes TFF membranes | TFF with 100 kDa MWCO; 5-10 diavolumes for >95% removal; low-salt initial buffer |
| Acetone | Thin-film hydration; sometimes combined with ethanol for solvent injection; less common in microfluidics | BP 56 °C; fully water-miscible; high vapor pressure; Class 3 solvent | Rotary evaporation (thin-film); TFF or dialysis (injection methods) |
| Methanol | Co-solvent with chloroform for lipids with limited ethanol solubility; dissolves polar lipids effectively | BP 65 °C; fully water-miscible; Class 2 solvent — more stringent residual limits than ethanol/acetone | Rotary evaporation with extended vacuum drying; verify residuals analytically |
| Chloroform | Historically most common thin-film solvent; excellent lipid solubility across all classes; declining use due to toxicity | BP 61 °C; density 1.49 g/mL (sinks); poorly water-miscible; Class 2 solvent; persistent trace residues possible | Rotary evaporation at 318-333 K + vacuum drying 4-8 h; GC-headspace verification; avoid in payload-contact processes |
| Dichloromethane (DCM) | Alternative to chloroform for thin-film methods; used in solvent emulsification-evaporation | BP 40 °C; density 1.33 g/mL; poorly water-miscible; Class 2 solvent; faster removal than chloroform | Rotary evaporation at 303-313 K + vacuum drying; faster kinetics than chloroform |
| Chloroform-Methanol Mixtures | Binary system for complex lipid mixtures; methanol dissolves polar lipids, chloroform dissolves hydrophobic lipids | Forms minimum-boiling azeotrope; methanol (65 °C) evaporates first, potentially altering lipid deposition pattern | Controlled-rate rotary evaporation; consider ethanol alternatives if lipid solubility permits |
| Ethanol-Acetone Mixtures | Some solvent injection protocols; combined properties improve dissolution or modify precipitation kinetics | Both fully water-miscible; acetone (56 °C) evaporates faster than ethanol (78 °C); both Class 3 | TFF or dialysis removes both simultaneously; evaporative methods must account for differential rates |
Solvent selection should balance three considerations: solubility (can it dissolve all lipid components?), removability (can it be reduced to safe levels with available equipment and acceptable processing time?), and safety (does its toxicological profile support the intended application?). For most modern LNP applications, ethanol excels across all three criteria. For thin-film hydration methods still using chlorinated solvents, LNP solvent screening services can evaluate ethanol-based alternatives.
Presentation: Residual solvent exceeds target after planned diafiltration volumes or dialysis exchanges — either systematically (consistent underperformance) or variably (batch-to-batch inconsistency at constant parameters).
Root Causes:
Solutions: Add 2-3 extra diavolumes; verify membrane integrity; reduce sample-to-dialysate ratio for dialysis; supplement TFF with terminal evaporation for volatiles; validate GC analytical method for all solvent species present. Efficiency testing for LNP encapsulation should accompany solvent analysis to confirm that protocol adjustments preserve payload retention.
Presentation: Mean diameter increases during/after solvent removal; PDI rises; secondary large-particle population appears; in severe cases, visible precipitates form.
Root Causes:
Solutions: Reduce solvent removal rate (TFF flux from 30 to 10-15 LMH); verify low ionic strength of initial diafiltration buffer; increase PEG-lipid by 0.5-1.0 mol% for enhanced steric stabilization; introduce an intermediate hold step at the ethanol concentration where aggregation initiates.
Presentation: Post-removal encapsulation efficiency significantly below pre-removal value. For mRNA-LNPs, reduced in vitro translation may indicate degradation even if EE% appears acceptable.
Root Causes:
Solutions: Strict low-salt initial diafiltration; reduce TMP to 1.0-2.0 psi; add RNase inhibitors for mRNA; reduce MWCO to 30-50 kDa for siRNA; payload retention testing for LNP encapsulation should quantify cargo loss at each process stage.
Presentation: Total LNP mass/particle count 10-30% below expected input. Loss not explained by aggregation or leakage, indicating nonspecific surface adsorption.
Root Causes:
Solutions: Pre-condition membranes with dilute lipid or surfactant buffer to saturate adsorption sites; select hydrophilic mPES over PS or PVDF; minimize tubing diameter and length; add inert carrier protein (0.1% BSA) at small scale. Troubleshooting services for LNP encapsulation at BOC Sciences provide systematic mass balance analysis to identify dominant loss mechanisms and develop targeted mitigation strategies.
Tell us about the difficulties you are experiencing with LNP solvent removal. BOC Sciences combines extensive experience with specialized technical capabilities to identify the underlying cause and develop a solution tailored to your LNP process.
BOC Sciences provides integrated scientific support across the LNP solvent removal workflow — from solvent selection and method feasibility assessment through TFF parameter optimization and process scale-up. The table below summarizes our core service offerings in this area.
Table 5. BOC Sciences Services for LNP Solvent Removal and Manufacturing Process Development.
| Service | Scope | Key Deliverables | Inquiry |
| LNP Solvent Screening and Feasibility Assessment | Evaluation of solvent options (ethanol, acetone, alternative solvents) for lipid solubility, removability, and payload compatibility; mixed-solvent system optimization | Solvent selection report with removal feasibility data; recommended solvent system for target formulation | Inquiry |
| TFF and Diafiltration Process Development | Membrane screening (MWCO, chemistry, format); TMP/flux/diafiltration volume optimization; buffer transition protocol development; PAT integration | Optimized TFF process with defined CPP ranges; process development report; 3 consistency batches | Inquiry |
| LNP Process Scale-Up Services | Scale-up from laboratory (mL) to pilot (L) and pilot and production scales; hollow fiber TFF implementation; continuous manufacturing integration | Scalable manufacturing process; scale-up comparability data; technology transfer documentation | Inquiry |
| LNP Buffer Screening Services | Screening of diafiltration buffers (citrate, acetate, Tris, PBS); ionic strength and pH optimization for each solvent removal stage; cryoprotectant selection | Buffer compatibility matrix; optimized buffer transition protocol; stability data under process conditions | Inquiry |
| Post-Removal LNP Characterization | DLS, zeta potential, cryo-EM, NTA; encapsulation efficiency; residual solvent analysis (GC-headspace); payload integrity assessment; in vitro potency | Comprehensive characterization report; CQA data package for each process condition | Inquiry |
| Solvent Removal Troubleshooting | Root-cause investigation of recovery loss, aggregation, leakage, or inconsistent clearance; mass balance analysis; membrane-surface analytics; process re-optimization | Root cause analysis report; revised process with demonstrated resolution; mitigation strategy documentation | Inquiry |
Solvent removal is a process-defining unit operation in LNP manufacturing whose execution directly shapes particle size, encapsulation efficiency, colloidal stability, payload integrity, and batch consistency. The method must be matched to production scale — from laboratory dialysis through pilot TFF to commercial hollow fiber manufacturing — as well as to solvent chemistry and payload sensitivity. In practice, development teams encounter real-world challenges: incomplete solvent clearance, particle aggregation during buffer transition, payload leakage from premature salt introduction or excessive shear, and material loss through membrane adsorption. These issues often arise at the interface between unit operations and require integrated process understanding to resolve.
BOC Sciences addresses these challenges through comprehensive, stage-appropriate support. Our lipid nanoparticle formulation services incorporate solvent selection and removal feasibility from early development. LNP process optimization and LNP process scale-up services provide systematic TFF development and technology transfer from benchtop to production. Post-removal lipid nanoparticle characterization verifies solvent clearance without CQA compromise, and troubleshooting services for LNP encapsulation deliver root-cause investigation when unexpected problems arise. This integrated approach ensures solvent removal is developed as a robust, well-characterized component of the overall LNP manufacturing process.
